<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761616</url>
  </required_header>
  <id_info>
    <org_study_id>ML30038</org_study_id>
    <nct_id>NCT02761616</nct_id>
  </id_info>
  <brief_title>A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a retrospective, and observational cohort study to determine the proportion of breast
      cancer first relapses, that are biopsied. The duration of the study will be approximately 24
      months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of biopsied participants with metastatic relapse</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of non-biopsied participants at first relapse according to different reasons for not performing a biopsy of the metastasis</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of biopsied and non-biopsied participants at first relapse metastatic breast cancer (mBC) for each metastatic site</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of biopsied participants at first relapse mBC according to each biopsy method</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of biopsied and non- biopsied participants at first relapse mBC for each molecular profile of primary tumor</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of biopsied participants at first relapse mBC for each molecular profile of biopsied metastases</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of biopsied participants at first relapse mBC with same and different molecular profiles between primary tumor and metastasis for each molecular profile</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with type of first line therapy selected for metastatic disease</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants influenced with biopsy in mBC</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of biopsied and non- biopsied participants at first relapse mBC for each systemic treatment scheme in the adjuvant and in the metastatic setting</measure>
    <time_frame>Approximately up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">76</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>eBC treated participants</arm_group_label>
    <description>Participants with metastatic disease after previously being treated for eBC were observed for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>eBC treated participants</intervention_name>
    <description>No intervention administered in this retrospective observational study.</description>
    <arm_group_label>eBC treated participants</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with a first relapse of breast cancer after being treated for eBC.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with histologically confirmed breast cancer treated for early breast
             cancer (eBC) with first metastatic relapse disease in the period from January 1, 2014
             and December 31, 2015

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cemic; Oncologia Clinica</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mor√≥n</name>
      <address>
        <city>Moron</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CENICLAR</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <zip>T4000IAK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

